Stocks · News reference
Filed: 2026-10-14 AccNo: 0001104659-26-115709 Size: 212 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe
Analysts initiated coverage on ASBH, QNRX, AXGN and HOOD with bullish ratings and targets; IDXX received a Sector Weight rating.
BTIG analyst Jeet Mukherjee initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $14.